There are 2758 resources available
Topic 3 case presentation: Side effects of TKI’s
Presenter: Stefan Rauh
Session: Treatment decisions and side effect management of new drugs (including immunotherapy) in lung cancer
Resources:
Slides
Webcast
Treatment decisions and side effect management of new drugs (including immunotherapy) in lung cancer - General Discussion
Presenter: Pilar Garrido Lopez
Session: Treatment decisions and side effect management of new drugs (including immunotherapy) in lung cancer
Resources:
Slides
Webcast
1735 - Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)
Presenter: Enriqueta Felip
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
2521 - Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L trial
Presenter: Sanjay Popat
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
5074 - Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study
Presenter: Rafal Dziadziuszko
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
4315 - Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
Presenter: Benjamin Solomon
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
1727 - Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC ASCEND-8)
Presenter: Byoung Chul Cho
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
Poster Discussion session - NSCLC, metastatic 1 - Invited Discussant LBA57, LBA58, 1379PD, 1380PD and LBA59
Presenter: Pasi Janne
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Slides
Webcast
1458 - Uncommon EGFR mutations in lung adenocarcinomas: clinical features and response to tyrosine kinase inhibitors
Presenter: Aurélien Brindel
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
1404 - Gefitinib With or Without Pemetrexed in Nonsquamous (NS) Non–Small Cell Lung Cancer (NSCLC) With EGFR Mutation (mut): Final Overall Survival (OS) Results From a Randomized Phase II Study
Presenter: James Chih-Hsin Yang
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.